Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
United Therapeutics Corporation is a biotechnology business based in the US. United Therapeutics Corporation shares (UTHR) are listed on the NASDAQ and all prices are listed in US Dollars. United Therapeutics Corporation employs 920 staff and has a trailing 12-month revenue of around USD$1.4 billion.
|Latest market close||USD$134.65|
|52-week range||USD$75.58 - USD$144.26|
|50-day moving average||USD$131.8837|
|200-day moving average||USD$117.0979|
|Wall St. target price||USD$154.8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$10.59|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-13)||N/A|
|1 month (2020-12-24)||-10.13%|
|3 months (2020-10-20)||N/A|
|6 months (2020-07-20)||N/A|
|1 year (2020-01-20)||N/A|
|2 years (2019-01-20)||N/A|
|3 years (2018-01-20)||N/A|
|5 years (2016-01-20)||N/A|
Valuing United Therapeutics Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of United Therapeutics Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
United Therapeutics Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, United Therapeutics Corporation shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
United Therapeutics Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 7.8048. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into United Therapeutics Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
United Therapeutics Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$642.3 million.
The EBITDA is a measure of a United Therapeutics Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.4 billion|
|Operating margin TTM||42.07%|
|Gross profit TTM||USD$1.3 billion|
|Return on assets TTM||8.81%|
|Return on equity TTM||15.62%|
|Market capitalisation||USD$5.8 billion|
TTM: trailing 12 months
There are currently 2.2 million United Therapeutics Corporation shares held short by investors – that's known as United Therapeutics Corporation's "short interest". This figure is 11.5% down from 2.5 million last month.
There are a few different ways that this level of interest in shorting United Therapeutics Corporation shares can be evaluated.
United Therapeutics Corporation's "short interest ratio" (SIR) is the quantity of United Therapeutics Corporation shares currently shorted divided by the average quantity of United Therapeutics Corporation shares traded daily (recently around 550822.52475248). United Therapeutics Corporation's SIR currently stands at 4.04. In other words for every 100,000 United Therapeutics Corporation shares traded daily on the market, roughly 4040 shares are currently held short.
However United Therapeutics Corporation's short interest can also be evaluated against the total number of United Therapeutics Corporation shares, or, against the total number of tradable United Therapeutics Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case United Therapeutics Corporation's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 United Therapeutics Corporation shares in existence, roughly 50 shares are currently held short) or 0.057% of the tradable shares (for every 100,000 tradable United Therapeutics Corporation shares, roughly 57 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against United Therapeutics Corporation.
Find out more about how you can short United Therapeutics Corporation stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like United Therapeutics Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 35.51
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and United Therapeutics Corporation's overall score of 35.51 (as at 01/01/2019) is nothing to write home about – landing it in it in the 54th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like United Therapeutics Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 6.16/100
United Therapeutics Corporation's environmental score of 6.16 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 24.94/100
United Therapeutics Corporation's social score of 24.94 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 17.41/100
United Therapeutics Corporation's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that United Therapeutics Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. United Therapeutics Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that United Therapeutics Corporation has, for the most part, managed to keep its nose clean.
|Total ESG score||35.51|
|Total ESG percentile||53.55|
|Environmental score percentile||9|
|Social score percentile||9|
|Governance score percentile||9|
|Level of controversy||2|
We're not expecting United Therapeutics Corporation to pay a dividend over the next 12 months.
United Therapeutics Corporation's shares were split on a 2:1 basis on 23 September 2009. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your United Therapeutics Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for United Therapeutics Corporation shares which in turn could have impacted United Therapeutics Corporation's share price.
Over the last 12 months, United Therapeutics Corporation's shares have ranged in value from as little as $75.58 up to $144.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while United Therapeutics Corporation's is 0.4829. This would suggest that United Therapeutics Corporation's shares are less volatile than average (for this exchange).
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.